Pulse Biosciences, Inc.PLSE

NasdaqHealthcareSurgical & Medical Instruments & Apparatus
Price (close)
$51.83
Market cap
$3.7B
P/E
—
Revenue (TTM)
$1.2M
Net income
-$80.1M
Dividend yield
—
1-year total return
203.3%
Net margin
-6755.8%
Revenue growth
—
Debt / equity
—

What Pulse Biosciences, Inc. does.

We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. We developed our proprietary nPulse System (formerly known as CellFX), a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of the skin. In parallel, we have designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and otolaryngology. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, we decided in 2022 to focus our primary efforts on the use of nsPFA energy and the nPulse platform in the treatment of atrial fibrillation, where approximately 1.9 million patients in the United States are diagnosed annually. This potentially represents a greater than $3.0 billion addressable market within electrophysiology alone combined with long-term double-digit growth. Additionally, we are also pursuing the treatment of atrial fibrillation via a surgical approach as well as select other markets where nsPFA technology could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$0$1.4M$700,000$0$0$350,000
Net income-$49.9M-$63.7M-$58.5M-$42.2M-$53.6M-$72.8M
Free cash flow-$35.8M-$54.5M-$47.4M-$33.2M-$36.5M-$54.4M

More on PLSE.

Figures from Pulse Biosciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.